Evidence-based timing-of-delivery recommendations for common maternal, fetal, placental, and obstetric conditions
Important
This reference is intended for clinician education and clinical decision-support development.
Recommendations must be individualized according to:
- Maternal condition
- Fetal condition
- Gestational age
- Accuracy of pregnancy dating
- Labor status
- Membrane status
- Vaginal bleeding
- Fetal surveillance
- Coexisting diagnoses
- Patient preferences
- Institutional maternal and neonatal capabilities
Maternal or fetal deterioration supersedes routine gestational-age recommendations.
Note
Status: Published clinical reference
Version: 1.0
Guideline review: July 2026
Primary sources: ACOG and SMFM
Maintainer: Dr. Chukwuma Onyeije
Unless otherwise specified, the recommendations below assume:
- Reliable pregnancy dating
- Stable maternal condition
- Reassuring fetal surveillance
- No labor
- Intact membranes
- No significant vaginal bleeding
- No separate indication for earlier delivery
Gestational ages are expressed as completed weeks and days.
For example:
37 0/7 weeks = 37 weeks and 0 days
37 6/7 weeks = 37 weeks and 6 days
- Hypertensive disorders
- Diabetes in pregnancy
- Fetal growth restriction
- Amniotic-fluid disorders
- Multiple gestation
- Intrahepatic cholestasis
- Placental and fetal-vessel disorders
- Prelabor rupture of membranes
- Prior uterine surgery
- Fetal anemia and alloimmunization
- Advanced maternal age
- Conditions requiring individualized timing
| Condition | Clinical Status | Recommended Delivery |
|---|---|---|
| Gestational hypertension | No severe features | 37 0/7 weeks |
| Preeclampsia | No severe features | 37 0/7 weeks |
| Gestational hypertension | Severe-range blood pressure | Manage as preeclampsia with severe features |
| Preeclampsia with severe features | At or beyond 34 0/7 weeks | Delivery after maternal stabilization |
| Preeclampsia with severe features | Before 34 0/7 weeks and stable | Carefully selected inpatient expectant management may be considered |
| Eclampsia | Any viable gestational age | Delivery after stabilization |
| HELLP syndrome | Any viable gestational age | Delivery after stabilization |
| Chronic hypertension | Not requiring medication | 38 0/7–39 6/7 weeks |
| Chronic hypertension | Controlled with medication | 37 0/7–39 6/7 weeks |
| Chronic hypertension | Difficult to control | 36 0/7–37 6/7 weeks, individualized |
| Superimposed preeclampsia | Without severe features | 37 0/7 weeks |
| Superimposed preeclampsia | With severe features | Follow severe-feature recommendations |
- Uncontrolled acute severe hypertension
- Eclampsia
- Pulmonary edema
- Stroke
- Myocardial infarction
- HELLP syndrome
- Progressive renal dysfunction
- Persistent refractory headache
- Persistent visual symptoms
- Persistent right-upper-quadrant or epigastric pain
- Placental abruption
- Nonreassuring fetal status
- Other progressive maternal or fetal deterioration
Warning
An indicated delivery at or beyond 34 weeks for preeclampsia with severe features should not be delayed solely to complete antenatal corticosteroids.
Primary source: ACOG Practice Bulletin No. 222; ACOG Committee Opinion No. 831.
| Condition | Glycemic Status | Recommended Delivery |
|---|---|---|
| Gestational diabetes, A1GDM | Diet controlled | 39 0/7–40 6/7 weeks |
| Gestational diabetes, A2GDM | Well controlled with medication | 39 0/7–39 6/7 weeks |
| Gestational diabetes | Poorly controlled | Individualize; commonly 37 0/7–38 6/7 weeks |
| Pregestational type 1 or type 2 diabetes | Well controlled without vascular complications | 39 0/7–39 6/7 weeks |
| Pregestational diabetes | Poor glycemic control, vascular disease, or prior stillbirth | 36 0/7–38 6/7 weeks, individualized |
- Persistent poor glycemic control despite treatment
- Diabetic ketoacidosis with maternal or fetal instability
- Preeclampsia
- Abnormal fetal surveillance
- Fetal growth restriction
- Significant vascular or renal disease
- Other maternal or fetal complications
Note
Suspected macrosomia alone does not automatically establish an indication for delivery before 39 weeks.
Primary sources: ACOG Practice Bulletin on Gestational Diabetes Mellitus; ACOG Practice Bulletin on Pregestational Diabetes Mellitus; ACOG Committee Opinion No. 831.
| FGR Category | Umbilical-Artery Doppler | Recommended Delivery |
|---|---|---|
| EFW 3rd–10th percentile | Normal | 38 0/7–39 0/7 weeks |
| Severe FGR: EFW below 3rd percentile | No absent or reversed flow | 37 0/7 weeks |
| FGR | Decreased diastolic flow, but no AEDV or REDV | 37 0/7 weeks |
| FGR | Absent end-diastolic velocity: AEDV | 33 0/7–34 0/7 weeks |
| FGR | Reversed end-diastolic velocity: REDV | 30 0/7–32 0/7 weeks |
FGR management should incorporate:
- Gestational age
- Interval growth
- Umbilical-artery Doppler
- Fetal testing
- Amniotic-fluid volume
- Maternal disease
- Associated fetal anomalies
- Complete clinical trajectory
- Nonreassuring antenatal testing
- Progressive Doppler deterioration
- Maternal deterioration
- Severe preeclampsia
- Placental abruption
- Other evidence that continued pregnancy is unsafe
Note
Routine use of middle cerebral artery, ductus venosus, or uterine artery Doppler is not recommended by SMFM for the routine management of otherwise uncomplicated FGR.
Primary source: SMFM Consult Series No. 52; ACOG Practice Bulletin No. 227.
| Condition | Clinical Status | Recommended Delivery |
|---|---|---|
| Isolated oligohydramnios | Otherwise uncomplicated | 36 0/7–37 6/7 weeks, or at diagnosis if later |
| Mild idiopathic polyhydramnios | Otherwise uncomplicated | Allow spontaneous labor at term; avoid planned delivery before 39 0/7 weeks without another indication |
| Moderate or severe polyhydramnios | Stable | Individualize according to etiology, fetal condition, symptoms, and surveillance |
- Abnormal fetal surveillance
- Rupture of membranes
- Labor
- Significant maternal respiratory symptoms
- Cord prolapse
- Placental abruption
- Fetal anomaly requiring coordinated delivery
- Other maternal or fetal indications
Primary sources: ACOG Committee Opinion No. 831; SMFM Consult Series on polyhydramnios.
| Chorionicity / Amnionicity | Recommended Delivery |
|---|---|
| Dichorionic diamniotic twins | 38 0/7–38 6/7 weeks |
| Monochorionic diamniotic twins | 36 0/7–37 0/7 weeks |
| Monochorionic monoamniotic twins | 32 0/7–34 0/7 weeks by planned cesarean delivery |
| Pregnancy Type | Recommended Approach |
|---|---|
| Uncomplicated trichorionic triamniotic triplets | Commonly plan delivery during the 35th week |
| Other triplet or higher-order gestations | Individualize with maternal-fetal medicine input |
- Twin-twin transfusion syndrome
- Twin anemia-polycythemia sequence
- Selective fetal growth restriction
- Abnormal Doppler findings
- Discordant growth with fetal compromise
- Preeclampsia
- Preterm labor
- Rupture of membranes
- Abnormal fetal surveillance
- Fetal demise
- Other maternal or fetal deterioration
Important
These windows apply to uncomplicated pregnancies. Complicated monochorionic gestations require condition-specific planning.
Primary sources: ACOG Practice Bulletin No. 231; SMFM 2026 Updated Checklists for Management of Monochorionic Twin Pregnancy; ACOG Committee Opinion No. 831.
| Peak Total Bile Acids | Recommended Delivery |
|---|---|
| At least 100 µmol/L | 36 0/7 weeks |
| Below 100 µmol/L | 36 0/7–39 0/7 weeks |
| Clinical symptoms without laboratory confirmation | Do not deliver before 37 weeks solely for suspected ICP |
Within the 36–39-week window, timing should consider:
- Peak bile-acid concentration
- Severity and persistence of pruritus
- Prior stillbirth associated with ICP
- Coexisting preeclampsia or diabetes
- Fetal surveillance
- Shared decision-making
Note
SMFM recommends antenatal corticosteroids when delivery before 37 0/7 weeks is planned and a prior course has not been administered.
Primary source: SMFM Consult Series No. 53, endorsed by ACOG.
| Condition | Stable Clinical Status | Recommended Delivery |
|---|---|---|
| Placenta previa | No active bleeding or other complication | 36 0/7–37 6/7 weeks |
| Placenta accreta spectrum | Stable, planned cesarean delivery or cesarean hysterectomy | 34 0/7–35 6/7 weeks |
| Vasa previa | Prenatally diagnosed and stable | Planned cesarean delivery 34 0/7–37 0/7 weeks |
| Chronic placental abruption | Stable maternal and fetal status | Individualize; no single universal gestational-age recommendation |
| Acute placental abruption | Maternal or fetal compromise | Immediate delivery as clinically indicated |
Delivery should occur at a center with:
- Appropriate maternal level of care
- Experienced multidisciplinary surgical team
- Blood-bank and massive-transfusion capability
- Critical-care support
- Neonatal support
Delivery timing should consider:
- Symptoms
- Cervical length
- Prior preterm birth
- Contractions
- Bleeding
- Distance from hospital
- Inpatient versus outpatient management
- Local neonatal resources
Warning
With known vasa previa, labor or rupture of membranes generally requires urgent cesarean delivery.
Primary sources: ACOG–SMFM Obstetric Care Consensus No. 7; SMFM Consult Series No. 37; ACOG Committee Opinion No. 831.
| Membrane Status | Gestational Age | Recommended Approach |
|---|---|---|
| Term PROM | At least 37 0/7 weeks | Recommend delivery |
| PPROM | 24 0/7–33 6/7 weeks | Expectant inpatient management when no contraindication exists |
| Late-preterm PPROM | 34 0/7–36 6/7 weeks | Delivery or expectant management may be reasonable after counseling; do not continue beyond 37 0/7 weeks |
| Previable or periviable PPROM | Before threshold of planned neonatal resuscitation | Individualized counseling and management |
- Intraamniotic infection
- Placental abruption
- Nonreassuring fetal status
- Advanced labor
- Cord prolapse
- Significant hemorrhage
- Maternal instability
- Other contraindication to continued pregnancy
Note
Management should also address latency antibiotics, antenatal corticosteroids, magnesium sulfate for fetal neuroprotection when indicated, and group B streptococcal prophylaxis.
Primary source: ACOG Practice Bulletin No. 217.
| Uterine History | Recommended Delivery |
|---|---|
| Prior classical cesarean incision | 36 0/7–37 0/7 weeks |
| Prior T-shaped uterine incision | 36 0/7–37 0/7 weeks |
| Prior uterine rupture | 36 0/7–37 0/7 weeks, individualized |
| Prior myomectomy requiring cesarean delivery | 37 0/7–38 6/7 weeks |
| Prior low-transverse cesarean, no contraindication to labor | Timing based on usual obstetric indications and TOLAC plan |
Timing should incorporate:
- Whether the endometrial cavity was entered
- Number, size, and location of fibroids removed
- Surgical approach
- Extent of myometrial dissection
- Operative report
- Surgeon’s recommendation
- Prior pregnancy outcomes
Note
More extensive uterine surgery may justify delivery closer to 37 weeks, whereas less extensive surgery may permit delivery closer to 38 6/7 weeks.
Primary source: ACOG Committee Opinion No. 831; ACOG Practice Bulletin on vaginal birth after cesarean delivery.
| Clinical Status | Recommended Delivery |
|---|---|
| Fetus at significant risk of anemia but stable | 37 0/7–38 0/7 weeks |
| Pregnancy following intrauterine transfusion | Individualize according to timing of final transfusion, fetal condition, and treatment-center protocol |
| Hydrops or evidence of severe fetal anemia | Fetal therapy or delivery according to gestational age and comparative procedural risk |
- Hydrops
- MCA peak systolic velocity suggesting severe anemia
- Abnormal fetal surveillance
- Inability to safely continue fetal therapy
- Maternal or fetal deterioration
Primary source: SMFM Clinical Guideline No. 8, reaffirmed 2025.
| Maternal Age at Anticipated Delivery | Recommended Approach |
|---|---|
| 35–39 years without another complication | Routine obstetric timing; age alone does not mandate early-term delivery |
| 40 years or older | Proceed with delivery during 39 0/7–39 6/7 weeks in a well-dated pregnancy |
Note
Earlier delivery should be based on an additional maternal, fetal, or obstetric indication rather than chronological age alone.
Primary source: ACOG–SMFM Obstetric Care Consensus: Pregnancy at Age 35 Years or Older.
ACOG or SMFM does not provide one universal gestational-age window for every clinical disorder.
The following commonly require individualized multidisciplinary planning:
| Condition | Major Factors Determining Timing |
|---|---|
| Maternal cardiac disease | Cardiac lesion, ventricular function, symptoms, anticoagulation, hemodynamic risk |
| Chronic kidney disease | Renal function, hypertension, proteinuria, fetal growth, superimposed preeclampsia |
| Systemic lupus erythematosus | Disease activity, nephritis, hypertension, fetal condition |
| Antiphospholipid syndrome | Thrombosis history, anticoagulation, placental dysfunction, fetal surveillance |
| Pulmonary hypertension | Maternal hemodynamics and tertiary-care planning |
| Major fetal anomaly | Prognosis, fetal condition, need for neonatal surgery, delivery-center capability |
| Hydrops fetalis | Etiology, fetal therapy options, gestational age, surveillance |
| Chronic placental abruption | Bleeding, maternal status, fetal growth, testing, gestational age |
| Severe polyhydramnios | Etiology, maternal symptoms, fetal anomaly, labor risk |
| Prior stillbirth | Etiology, recurrence risk, surveillance, anxiety, neonatal risk of early delivery |
| IVF pregnancy | Obstetric complications and shared decision-making; consider delivery at 39 weeks where appropriate |
| Extreme obesity | Age, comorbidities, surveillance, cervical status, and local induction policy |
For these conditions, the table should not substitute for:
- MFM consultation
- Relevant medical-subspecialty consultation
- Anesthesia planning
- Neonatology planning
- Shared decision-making
- Institutional protocol
Examples include:
- Eclampsia
- Stroke
- Pulmonary edema
- Uncontrolled severe hypertension
- Significant hemorrhage
- Placental abruption
- Intraamniotic infection
- Cord prolapse
- Persistent Category III fetal heart-rate tracing
- Abnormal fetal surveillance
- Fetal death
- Other evidence that continued pregnancy presents greater risk than delivery
Administer antenatal corticosteroids when indicated and when delivery is expected within the recommended interval.
An urgent or otherwise indicated delivery should not be delayed solely to complete a corticosteroid course.
Administer magnesium sulfate when indicated for:
- Maternal seizure prophylaxis
- Fetal neuroprotection when early preterm delivery is anticipated
The recommended gestational age does not independently determine:
- Induction versus cesarean delivery
- Trial of labor after cesarean eligibility
- Operative-vaginal delivery
- Need for classical cesarean
- Delivery location
Mode and location of delivery require separate assessment.
In the absence of a maternal, fetal, placental, or obstetric indication:
- Avoid nonmedically indicated delivery before 39 0/7 weeks.
- Do not use fetal lung-maturity testing to justify an otherwise nonmedically indicated early-term delivery.
| Abbreviation | Meaning |
|---|---|
| ACOG | American College of Obstetricians and Gynecologists |
| SMFM | Society for Maternal-Fetal Medicine |
| AEDV | Absent end-diastolic velocity |
| REDV | Reversed end-diastolic velocity |
| EFW | Estimated fetal weight |
| FGR | Fetal growth restriction |
| ICP | Intrahepatic cholestasis of pregnancy |
| PPROM | Preterm prelabor rupture of membranes |
| PROM | Prelabor rupture of membranes |
-
American College of Obstetricians and Gynecologists.
Medically Indicated Late-Preterm and Early-Term Deliveries.
Committee Opinion No. 831. 2021. -
American College of Obstetricians and Gynecologists.
Gestational Hypertension and Preeclampsia.
Practice Bulletin No. 222. 2020. -
American College of Obstetricians and Gynecologists.
Prelabor Rupture of Membranes.
Practice Bulletin No. 217. -
American College of Obstetricians and Gynecologists.
Gestational Diabetes Mellitus.
Practice Bulletin No. 190. -
American College of Obstetricians and Gynecologists.
Pregestational Diabetes Mellitus.
Practice Bulletin No. 201. -
American College of Obstetricians and Gynecologists.
Fetal Growth Restriction.
Practice Bulletin No. 227. -
American College of Obstetricians and Gynecologists.
Multifetal Gestations: Twin, Triplet, and Higher-Order Multifetal Pregnancies.
Practice Bulletin No. 231. -
American College of Obstetricians and Gynecologists and Society for Maternal-Fetal Medicine.
Placenta Accreta Spectrum.
Obstetric Care Consensus No. 7. -
American College of Obstetricians and Gynecologists and Society for Maternal-Fetal Medicine.
Pregnancy at Age 35 Years or Older.
Obstetric Care Consensus. -
Society for Maternal-Fetal Medicine.
Diagnosis and Management of Fetal Growth Restriction.
Consult Series No. 52. Reaffirmed 2024. -
Society for Maternal-Fetal Medicine.
Intrahepatic Cholestasis of Pregnancy.
Consult Series No. 53. Reaffirmed 2024 and endorsed by ACOG. -
Society for Maternal-Fetal Medicine.
Diagnosis and Management of Vasa Previa.
Consult Series No. 37. Reaffirmed 2024. -
Society for Maternal-Fetal Medicine.
The Fetus at Risk for Anemia: Diagnosis and Management.
Clinical Guideline No. 8. Reaffirmed 2025. -
Society for Maternal-Fetal Medicine.
Updated Checklists for Management of Monochorionic Twin Pregnancy.
Special Statement. 2026.
| Version | Date | Change |
|---|---|---|
| 0.1 | July 2026 | Initial framework |
| 1.0 | July 2026 | Added core ACOG and SMFM delivery recommendations |
Status: Published clinical reference
Version: 1.0
Last reviewed: July 2026
Next scheduled review: January 2027
Maintainer: Dr. Chukwuma Onyeije
Project: OpenMFM Clinical Reference Library
Website: https://openmfm.org
Blog: https://doctorswhocode.blog